Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication of some new data from an early stage clinical trial on Nov. 16 and its third-quarter earnings on Nov. 7.Usually, updates like those two would act as positive catalysts for a stock, assuming there was good news to share.In this case, there wasn't exactly any bad news, but the stock is clearly still smarting from the damage in October, when some clinical results from its gene editing program for hereditary angioedema (HAE) didn't stack up very favorably against a competitor's candidate.So is this stock still worth a purchase, or is there a problem that's starting to pick up speed?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool